Induction Therapy
Information
- Drug Name
- Induction Therapy
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| acute myeloid leukemia |
NPM1 p.Trp288CysfsTer12 (p.W288Cfs*12) ( ENST00000296930.10, ENST00000351986.10, ENST00000517671.5, ENST00000521672.6, ENST00000676589.1, ENST00000677297.1, ENST00000677325.1, ENST00000677357.1, ENST00000677907.1, ENST00000679190.1 ) NPM1 p.Trp288CysfsTer12 (p.W288Cfs*12) ( ENST00000679190.1, ENST00000677357.1, ENST00000296930.10, ENST00000351986.10, ENST00000517671.5, ENST00000521672.6, ENST00000676589.1, ENST00000677297.1, ENST00000677325.1, ENST00000677907.1 ) |
E |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 15659725 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| NPM1 mutation (Type A, W288fs) causes cytoplasmic ... | NPM1 |
NPM1 p.Trp288CysfsTer12 (p.W288Cfs*12) ( ENST00000296930.10, ENST00000351986.10, ENST00000517671.5, ENST00000521672.6, ENST00000676589.1, ENST00000677297.1, ENST00000677325.1, ENST00000677357.1, ENST00000677907.1, ENST00000679190.1 ) NPM1 p.Trp288CysfsTer12 (p.W288Cfs*12) ( ENST00000679190.1, ENST00000677357.1, ENST00000296930.10, ENST00000351986.10, ENST00000517671.5, ENST00000521672.6, ENST00000676589.1, ENST00000677297.1, ENST00000677325.1, ENST00000677907.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01781338 | Active, not recruiting | Phase 2/Phase 3 | Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer | May 2012 | October 2024 |
| NCT00923845 | Completed | Phase 2 | Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | March 1, 2008 | June 22, 2017 |
| NCT00207363 | Completed | Phase 4 | Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC | February 2002 | January 2010 |
| NCT01950819 | Completed | Phase 4 | Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) | December 3, 2013 | January 17, 2018 |
| NCT03644485 | Completed | Phase 4 | Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients | October 21, 2018 | July 15, 2022 |
| NCT04926584 | Recruiting | Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option | December 15, 2017 | December 31, 2027 | |
| NCT01005316 | Terminated | Alloantibodies in Pediatric Heart Transplantation | January 2010 | December 2014 | |
| NCT04849377 | Withdrawn | Phase 2 | RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC | June 14, 2022 | June 14, 2022 |